VAR2 Pharmaceuticals is attending the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona between 18-20 November 2026.
Our Executive Chairman of the Board Mads Daugaard will be accompanied by our Deputy Chief Medical Officer Thomas Clausen at the event. VAR2 Pharmaceuticals will feature a Late-breaking Poster Presentation (poster no. PB-011, abstract no. 26LBA) reporting on the results from our just completed Phase 0 Nuclear Imaging Basket Trial VARTUTRACE (NCT06645808).
We are looking forward to meeting old and new colleagues, and discussing potential synergies with our lead ADC program planned to start a Phase 1 in Q2 2027.